DU Researchers create molecule to cure Parkinson's Disease, check details

Professor Kim from McLean Hospital, Boston, has collaborated with the DU team in the research that started in 2012 and was patented in 2014. The DU team is headed by professor Diwan S Rawat. Professor Rawat is a fellow at the National Academy of Sciences and one of his areas of expertise is medicinal chemistry. Professor Kim is the director of the molecular neurobiology laboratory at McLean Hospital.

DU Researchers create molecule to cure Parkinson's Disease, check details

A group of researchers from Delhi University has come up with a molecule that they claim has been created to stop the death of the dopamine neuron in mice and this could lead to a breakthrough cure for Parkinson’s Disease. Studies on mice had shown that one of the molecules they had developed had curbed some of the main causes of Parkinson’s, the research team said. The human clinical trials have not been started yet. 

Professor Kim from McLean Hospital, Boston, has collaborated with the DU team in the research that started in 2012 and was patented in 2014. The DU team is headed by professor Diwan S Rawat. Professor Rawat is a fellow at the National Academy of Sciences and one of his areas of expertise is medicinal chemistry. Professor Kim is the director of the molecular neurobiology laboratory at McLean Hospital.

Professor Rawat said "that since 2012, the team had made substantial progress and identified five molecules that can be developed as a drug for treatment of Parkinson’s Disease."

"There were two main reasons behind the development of Parkinson’s Disease. In the human brain, there are billions of neurons, one of which is the dopamine neuron that regulates dopamine concentration in the brain. If somehow the concentration of dopamine decreases, symptoms of Parkinson’s appear. Another factor is the aggregation of a particular kind of protein in the brain. Unfortunately, there is no drug available which can either stop the death of the dopamine neuron or stop aggregation of the alpha synuclein protein,” Rawat said.

“Our team developed a molecule which stops the death of the dopamine neuron and regulates concentration of dopamine in the brain, apart from stopping the aggregation of the (alpha synuclein) protein. A series of experiments on animals has confirmed our findings,” Rawat said.

He further added that “the technology transfer has taken place as industry stakeholders have to be brought in for development of a drug. The molecule has been taken up by a Boston-based pharma company.”

Read More:

• DU PG Admissions 2023 To Be Solely On CUET PG Score, Check Details
• DU NCWEB Admissions 2023 To Be Done On Basis Of CUET PG Score, Check Details